Literature DB >> 15705879

Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.

Erik H van Beers1, Tibor van Welsem, Lodewyk F A Wessels, Yunlei Li, Rogier A Oldenburg, Peter Devilee, Cees J Cornelisse, Senno Verhoef, Frans B L Hogervorst, Laura J van't Veer, Petra M Nederlof.   

Abstract

BRCA1 or BRCA2 germline mutations cause approximately 30% of breast cancers within high-risk families. This represents 5% of total breast cancer incidence. Although BRCA1 and BRCA2 are both implicated in DNA repair and genome stability, it is unknown whether BRCA1 and BRCA2 are associated with similar or distinct diseases. In a previous study we reported that BRCA1-related breast carcinomas show a distinct genomic profile as determined by comparative genomic hybridization (CGH). We now hypothesize that, if functionally equivalent, mutations in BRCA1 and BRCA2 would result in similar genomic profiles in tumors. Here we report the chromosomal gains and losses as measured by CGH in 25 BRCA2-associated breast tumors and compared them with our existing 36 BRCA1 and 30 control profiles. We compared all chromosomal regions and determined the regions of differential gain or loss between tumor classes and controls. BRCA2 and control tumors have very similar genomic profiles. As a consequence, and in contrast to BRCA1-associated tumors, CGH profiles from BRCA2-associated tumors could not be distinguished from control tumors using the classification methodology as we have developed before. The largest number of significant differences existed between BRCA1 and controls, followed by BRCA1 compared with BRCA2, suggesting different tumor development pathways for BRCA1 and BRCA2.

Entities:  

Mesh:

Year:  2005        PMID: 15705879

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

2.  Expression of WTH3 in breast cancer tissue and the effects on the biological behavior of breast cancer cells.

Authors:  Lin Gan; Guoqing Zuo; Ting Wang; Jie Min; Yadong Wang; Yongyue Wang; Gang Lv
Journal:  Exp Ther Med       Date:  2015-04-29       Impact factor: 2.447

Review 3.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

Review 4.  Genomic instability in breast cancer: pathogenesis and clinical implications.

Authors:  Kevin A Kwei; Yvonne Kung; Keyan Salari; Ilona N Holcomb; Jonathan R Pollack
Journal:  Mol Oncol       Date:  2010-04-09       Impact factor: 6.603

5.  Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.

Authors:  Robert W Mutter; Nadeem Riaz; Charlotte Ky Ng; Rob Delsite; Salvatore Piscuoglio; Marcia Edelweiss; Luciano G Martelotto; Rita A Sakr; Tari A King; Dilip D Giri; Maria Drobnjak; Edi Brogi; Ranjit Bindra; Giana Bernheim; Raymond S Lim; Pedro Blecua; Alexis Desrichard; Dan Higginson; Russell Towers; Ruomu Jiang; William Lee; Britta Weigelt; Jorge S Reis-Filho; Simon N Powell
Journal:  J Pathol       Date:  2017-04-27       Impact factor: 7.996

Review 6.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

7.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Authors:  Olafur Andri Stefansson; Jon Gunnlaugur Jonasson; Oskar Thor Johannsson; Kristrun Olafsdottir; Margret Steinarsdottir; Sigridur Valgeirsdottir; Jorunn Erla Eyfjord
Journal:  Breast Cancer Res       Date:  2009-07-09       Impact factor: 6.466

10.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Authors:  Anita L Bane; Dushanthi Pinnaduwage; Sarah Colby; Michael Reedijk; Sean E Egan; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.